Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"
Status:
Recruiting
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in
certain subgroups of patients. To date, no treatment has been shown to be effective in
controlling this disease in hospitalized patients with moderate and / or severe cases of this
disease. Hydroxychloroquine and lopinavir / ritonavir have been shown to inhibit SARS-CoV
viral replication in experimental severe acute respiratory symptoms models and have similar
activity against SARS-CoV2. Although widely used in studies of critically ill patients, to
date, no study has demonstrated its role on the treatment of high-risk, newly diagnosed
patients with COVID-19 and mild symptoms.
Phase:
Phase 3
Details
Lead Sponsor:
Cardresearch
Collaborators:
Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA Cytel Inc.